About
Alpha-
Synuclein

The SPARK study is evaluating an investigational drug that targets alpha-synuclein (α-syn)—a molecule associated with Parkinson’s disease—which researchers believe may potentially help to slow or reduce disease progression.

To learn more, visit our list of
Resources, or download the study brochure.

RESOURCES

  • A
  • A
  • A
High-contrast Proceed

*Required fields